Is There a Generic for Apixaban (Eliquis)?

Generic apixaban tablets have been approved by the FDA, and multiple manufacturers now have authorization to produce them. For years, patent protections kept lower-cost versions off pharmacy shelves even after the first generic approval came through in late 2019. Those barriers have been falling, and generic apixaban is entering the U.S. market. The timeline, the savings, and the practical details of switching are all worth understanding, especially given that Eliquis is one of the most widely prescribed and most expensive brand-name drugs in the country.

Why It Took So Long After FDA Approval

The FDA first approved a generic version of apixaban in December 2019, but that approval did not translate into pills on pharmacy shelves. Bristol-Myers Squibb and Pfizer, the companies behind Eliquis, hold multiple patents covering the drug’s composition, formulation, and methods of use. Generic manufacturers challenged those patents, and the resulting litigation led to settlement agreements that set specific dates when each generic company could begin selling its product. Most of those settlement dates fell in the 2026 to 2028 window, which is why generic apixaban was effectively unavailable for years after technical approval.

That delay mattered enormously. Eliquis has consistently been one of the top-selling drugs in the United States by revenue, with annual sales exceeding $10 billion. During the years patients waited for generics, out-of-pocket costs remained steep for many, particularly those without robust prescription coverage. Some manufacturers managed to negotiate earlier launch dates or received court rulings that allowed them to enter the market ahead of the original settlement timelines, which is why generic availability has been gradually expanding.

What Generic Apixaban Costs Compared to Eliquis

The brand-name price for Eliquis has historically been around $500 to $600 per month at retail without insurance, though the actual amount patients pay varies wildly depending on their coverage. Generic versions typically launch at a significant discount, often 70 to 90 percent below the brand price once multiple manufacturers are competing. Early generic entrants sometimes price more modestly at first, with deeper discounts arriving as more competitors reach the market.

For many patients, the practical question is less about the sticker price and more about what their insurance plan’s copay or coinsurance looks like. Even with generics available, formulary placement matters. If your plan already covered Eliquis at a manageable copay, the switch to generic might not change your out-of-pocket cost dramatically. But if you were paying a large share of the brand price, or if you lacked drug coverage entirely, generics can cut your monthly expense to a fraction of what it was.

Medicare Price Negotiation and the Inflation Reduction Act

Apixaban was one of the first ten drugs selected for Medicare price negotiation under the Inflation Reduction Act, signed into law in 2022. The negotiated maximum fair price for apixaban was set at roughly $2,811 per year, compared to estimated Medicare net prices of about $3,708 per year before negotiation. That negotiated price takes effect for Medicare Part D enrollees beginning in 2026.

A cost-effectiveness analysis found that the negotiated price falls below the median value-based price at a commonly used threshold, meaning Medicare is getting apixaban at a rate that health economists consider a good deal relative to the clinical benefit the drug provides.¹ Separate modeling estimated that the annual price premium of apixaban over the older blood thinner warfarin could be justified at up to roughly $4,350 per year at standard willingness-to-pay thresholds.²

There is a real concern, however, that the negotiation process could backfire for some patients. If pharmacy benefit managers respond to lower negotiated prices by shifting apixaban to higher cost-sharing tiers, patients could actually end up paying more out of pocket. One analysis estimated that if the three largest pharmacy benefit managers moved all apixaban prescriptions to the highest formulary tier, patient copays could increase by hundreds of millions of dollars collectively, potentially leading to roughly 170,000 to 228,000 patients abandoning the drug. The resulting gap in treatment could mean tens of thousands of additional cardiovascular events and deaths.³ Whether this scenario plays out depends on how insurers and benefit managers actually restructure their formularies once both the negotiated price and generic competition are in play simultaneously.

Are Generic Versions Truly Equivalent

For FDA approval, a generic drug must demonstrate bioequivalence to the brand-name product. That means the generic delivers the same amount of active ingredient into the bloodstream at the same rate. The testing is done in healthy volunteers under controlled conditions, and the key measures of blood concentration must fall within a tight regulatory range of 80 to 125 percent of the brand’s values. Bioequivalence studies for apixaban formulations have confirmed that test products match the reference product on these parameters.⁴

In practical terms, this means a generic apixaban tablet should work the same way in your body as the Eliquis tablet it replaces. The active ingredient is identical. What may differ are the inactive ingredients: binders, fillers, coatings, and dyes. These differences are cosmetic for most people but can occasionally matter if you have a specific allergy or sensitivity to a particular inactive ingredient. If you notice any unexpected reaction after switching, it is worth checking the inactive ingredient list with your pharmacist.

The broader evidence on generic cardiovascular drugs is reassuring. Generics for other widely used heart medications have performed equivalently to their brand counterparts in large real-world studies. The FDA’s bioequivalence standard, while sometimes criticized for not testing every real-world scenario, has a strong track record for simple oral tablets like apixaban.

What the Dabigatran Experience Teaches Us

Apixaban is not the first newer blood thinner to go generic. Dabigatran (brand name Pradaxa) lost patent protection earlier, and generic versions are already on the market in several countries. The experience with dabigatran generics offers a useful preview of what to watch for, and it comes with a cautionary note.

The brand-name formulation of dabigatran uses a specialized capsule design to maintain the acidic environment the drug needs for proper absorption. Because of this complexity, standard bioequivalence testing in fasting, healthy volunteers may not capture differences that emerge when the drug is taken with food or alongside common medications like proton pump inhibitors, which reduce stomach acid. Researchers raised concerns that generic dabigatran products approved through standard testing might not behave identically under these real-world conditions.⁵

A separate pharmacometric analysis found that generic dabigatran with slightly lower blood levels than the brand was actually cost-effective and performed well, but generic versions with unusually high blood levels were not cost-effective and raised safety concerns. The takeaway was that cost-effectiveness of a generic blood thinner cannot simply be assumed.⁶ Apixaban’s formulation is simpler than dabigatran’s, which is a point in favor of expecting smoother generic performance. Apixaban does not rely on the same acid-dependent absorption mechanism, so the concerns that plagued dabigatran generics are less likely to apply.

Why Cost Matters So Much for Blood Thinners

Blood thinners only work if you take them consistently. Unlike a painkiller, where skipping a dose just means tolerating discomfort, skipping doses of apixaban leaves gaps in your protection against stroke and blood clots. A survey of patients with atrial fibrillation who were prescribed apixaban found that cost was one of the strongest predictors of poor adherence. Patients reporting cost-related barriers were about four times more likely to have low adherence scores compared to those without financial concerns.⁷

The same study identified other reasons people stop taking apixaban as prescribed, including the belief that they do not need the medication and fear of serious bleeding. But cost stood out as a modifiable barrier, the one most directly addressed by generic availability. When a drug goes from costing several hundred dollars a month to a fraction of that, the patients most likely to benefit are the ones who were rationing doses or abandoning treatment entirely because they could not afford it.

This is the broader public health argument for generic apixaban. In head-to-head comparisons, apixaban showed a lower combined risk of stroke and death compared to warfarin, along with a lower risk of bleeding. Treatment persistence was also highest with apixaban among the newer blood thinners, with about 82 percent of patients still taking it at follow-up, compared to roughly 64 percent for dabigatran and warfarin.⁸ If cost has been the main reason some patients switch to or stay on warfarin instead of apixaban, generic pricing removes that obstacle.

Ways to Reduce Your Costs Right Now

If you are still paying brand-name prices for Eliquis or are in a coverage gap, several strategies can bring your costs down while generic availability ramps up.

Manufacturer copay cards: Bristol-Myers Squibb offers a copay assistance program for Eliquis that can reduce your out-of-pocket cost significantly. These cards are available directly from the manufacturer’s website and are easy to sign up for. The catch is that they are only available to patients with private insurance. If you are on Medicare or Medicaid, federal law prohibits you from using them.⁹
Patient assistance programs: Both Bristol-Myers Squibb and Pfizer operate assistance programs for uninsured or underinsured patients. These typically provide the drug at no cost or at a deep discount, but you usually need to meet income eligibility requirements and complete an application.
Pharmacy shopping: Prices for the same drug can vary substantially between pharmacies, sometimes by hundreds of dollars. Discount tools and price comparison websites can show you which pharmacy near you has the lowest cash price. Mail-order pharmacies and some big-box retailers often have competitive pricing.
Ask about generic substitution: If generic apixaban is available in your area, ask your pharmacist whether they can fill your prescription with the generic. In most states, pharmacists can automatically substitute a generic unless your prescriber has specifically written “dispense as written” or “brand medically necessary.” You or your doctor may need to explicitly request the generic if your pharmacy defaults to the brand.

Copay cards deserve a particular note of caution. While they make the brand drug affordable in the short term, they can also mask the true cost and delay the financial pressure that encourages generic adoption. For patients with high-deductible plans, the copay card may not fully cover the cost early in the year before the deductible is met. And once a copay card’s annual maximum benefit is reached, you are back to paying the full copay or coinsurance for the remainder of the year.

How Apixaban Works and Why Formulation Matters

Apixaban belongs to a class of drugs known as direct oral anticoagulants. It works by blocking factor Xa, a protein that plays a central role in the chain of events that forms blood clots. By directly and selectively inhibiting factor Xa, apixaban slows down thrombin generation, which is the final step before a clot forms. This mechanism is reversible, meaning the drug’s effect wears off as it is cleared from the body, and it does not require the same dietary restrictions and frequent blood monitoring that warfarin demands.¹⁰

From a generic manufacturing standpoint, apixaban is a relatively straightforward small molecule. It does not have the complex delivery system challenges that made dabigatran generics worrisome. The drug is absorbed well without special formulation tricks, and it does not depend on a particular stomach pH to get into the bloodstream effectively. This is good news for the reliability of generic versions, because the simpler the formulation, the easier it is to match the brand product’s performance in the body.

That said, manufacturing apixaban tablets still requires careful attention to how the active ingredient is processed and combined with excipients. The drug has low water solubility, which means the particle size and how it is blended into the tablet can influence how quickly it dissolves and enters the bloodstream. Generic manufacturers must demonstrate that their process produces tablets that dissolve and absorb at the same rate as Eliquis, and this is precisely what the bioequivalence studies confirm before the FDA grants approval.

What to Tell Your Doctor When Switching

If you are currently on brand-name Eliquis and your pharmacy starts filling your prescription with generic apixaban, the transition should be seamless for most people. The dose stays the same, the dosing schedule stays the same, and you should not need any additional blood tests or monitoring when switching. Unlike warfarin, apixaban does not require INR testing, and that convenience carries over to the generic.

There are a few situations where the conversation with your doctor is worth having proactively. If you have a history of unusual drug sensitivities or allergies to specific inactive ingredients, reviewing the generic’s ingredient list makes sense. If you take other medications that interact with apixaban, such as certain antifungal drugs or HIV medications, confirm with your pharmacist that the generic product does not introduce any new interaction concerns through its inactive ingredients. And if you have kidney or liver impairment that already required a dose adjustment, make sure the generic is available in the specific strength you need.

Some patients feel uneasy about switching from a brand they trust to a generic, and that anxiety is understandable. The practical reassurance is that apixaban is a well-characterized molecule with straightforward pharmacology. It binds to its target reversibly and selectively, and its behavior in the body is predictable and well-studied.¹¹ The characteristics that make apixaban effective in the brand formulation are inherent to the molecule itself, not to the branding on the box. If the generic passes bioequivalence testing, it delivers the same molecule to the same place in your body at the same rate. For the overwhelming majority of patients, that is all that matters.

Patients on Warfarin Considering a Switch

The availability of affordable generic apixaban may prompt a different kind of conversation for patients who have been staying on warfarin primarily because of cost. Warfarin has been generic for decades and costs only a few dollars a month, which made it the default choice for patients who could not afford a newer blood thinner. But warfarin comes with well-known downsides: frequent blood tests to check your INR, dietary restrictions around vitamin K intake, and a narrower therapeutic window that makes dosing tricky.

In comparative studies, apixaban had a more favorable profile than warfarin across effectiveness, bleeding risk, and how long patients stayed on the drug.⁸ Patients whose INR is well-controlled and stable on warfarin may not see a dramatic clinical benefit from switching, because well-managed warfarin therapy is still effective. But patients who struggle with INR control, who find the monitoring burdensome, or who have had bleeding episodes on warfarin are the ones most likely to benefit. With generic apixaban bringing the cost closer to what warfarin costs with regular lab work factored in, the financial argument for staying on warfarin weakens considerably.

Switching from warfarin to apixaban is not something to do on your own. The transition involves stopping warfarin and starting apixaban at a specific point based on your INR level, and your doctor will want to manage that overlap carefully to avoid either a gap in protection or excessive anticoagulation. But it is a routine switch that clinicians are very familiar with, and it can typically be done without hospitalization.